Disease · MONDO_0018896
Comparisons in its trials22
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 22
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| NAC Group vs Placebo Group: The Incidence of TA-TMA. | 5 of 66 | 15 of 77 | 143 | NCT03252925 | Trial comparisons |
| NAC Group vs Placebo: deaths from any cause | 16 of 66 | 27 of 74 | 140 | NCT03252925 | Trial comparisons |
| NAC Group vs Placebo: serious adverse events | 0 of 66 | 0 of 74 | 140 | NCT03252925 | Trial comparisons |
| Caplacizumab (Treated in Study C301) vs Standard of Care (SoC) (Treated in Study C301): deaths from any cause | 0 of 75 | 1 of 29 | 104 | NCT02878603 | Trial comparisons |
| Caplacizumab (Treated in Study C301) vs Standard of Care (SoC) (Treated in Study C301): serious adverse events | 28 of 75 | 16 of 29 | 104 | NCT02878603 | Trial comparisons |
| Caplacizumab (Treated in Study C301) vs Standard of Care (SoC) (Treated in Study C301): Number of Participants With aTTP Related Deaths Reported During the Study | 0 of 49 | 1 of 29 | 78 | NCT02878603 | Trial comparisons |
| Caplacizumab vs Placebo: Mortality | 0 of 36 | 2 of 39 | 75 | NCT01151423 | Trial comparisons |
| Caplacizumab vs Placebo: Number and Percentage of Subjects With Complete Remission Following Initial Daily Plasma Exchange (PE) | 29 of 36 | 18 of 39 | 75 | NCT01151423 | Trial comparisons |
| Caplacizumab vs Placebo: Number and Percentage of Subjects With PE Related AEs | 20 of 36 | 20 of 39 | 75 | NCT01151423 | Trial comparisons |
| Caplacizumab vs Placebo: Number and Percentage of Subjects With Exacerbations of TTP | 3 of 36 | 11 of 39 | 75 | NCT01151423 | Trial comparisons |
| Caplacizumab vs Placebo: Number and Percentage of Subjects With Relapse of TTP | 11 of 36 | 3 of 39 | 75 | NCT01151423 | Trial comparisons |
| Caplacizumab vs Placebo: deaths from any cause | 0 of 35 | 2 of 37 | 72 | NCT01151423 | Trial comparisons |
| Caplacizumab vs Placebo: serious adverse events | 20 of 35 | 19 of 37 | 72 | NCT01151423 | Trial comparisons |
| Caplacizumab vs Placebo: Number of Participants Who Developed Treatment-emergent Anti-Drug Antibodies (ADA) | 3 of 32 | 0 of 30 | 62 | NCT01151423 | Trial comparisons |
| Prophylaxis Cohort I: TAK-755 Then SoC vs Prophylaxis Cohort II: SoC Then TAK-755: Number of Participants With Neutralizing Antibodies to ADAMTS13 During Prophylactic Treatment | 0 of 21 | 1 of 27 | 48 | NCT03393975 | Trial comparisons |
| Prophylaxis Cohort I: TAK-755 Then SoC vs Prophylaxis Cohort II: SoC Then TAK-755: Number of Participants With Anti-Chinese Hamster Ovary (Anti-CHO) Protein Antibodies During Prophylactic Treatment | 0 of 21 | 2 of 27 | 48 | NCT03393975 | Trial comparisons |
| Prophylaxis Cohort I: TAK-755 Then SoC vs Prophylaxis Cohort II: SoC Then TAK-755: Number of Participants With Total Binding Antibodies to ADAMTS13 During Prophylactic Treatment | 0 of 21 | 2 of 27 | 48 | NCT03393975 | Trial comparisons |
| Danazol, Plex, Steroids vs Historic Control: Number of Participants With Relapses | 1 of 9 | 4 of 20 | 29 | NCT00953771 | Trial comparisons |
| CSA Arm vs Prednisone Arm: Number of Participants With Exacerbations in the CSA/PEX Arm Compared to the Steroids/PEX Arm | 3 of 12 | 1 of 14 | 26 | NCT00713193 | Trial comparisons |
| CSA Arm vs Prednisone Arm: deaths from any cause | 1 of 12 | 1 of 14 | 26 | NCT00713193 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018896/comparisons